TY - JOUR TI - COVID-19: Infection Control and Treatment Strategyin Pediatric Age Group in Turkey AB - In December 2019, the novel coronavirus (2019-nCoV) infection originating from Wuhan, China, and causinga worldwide epidemic, was named ‘Coronavirus Disease 2019’ (COVID-19) by the World Health Organization(WHO) (1). The novel coronavirus was defined as SARS CoV-2 due to the similarity with severe acute respiratorysyndrome (SARS) coronavirus and SARS CoV-2 is the first coronavirus announced as a pandemic on 11 March2020 (2). In Turkey, the first case was declared on 11 March 2020 and the first death was announced on 17March 2020. While the reported deaths are relatively low, the incidence is rising rapidly in Turkey (3). SARS CoV-2 is a highly infectious virus that can be transmitted extremely quickly. The main routes of transmis sion of the virus are close contact with an infected person and droplets formed by the infected person’s coughingand sneezing. SARS CoV-2 can also be transmitted from contaminated environments to the nasal, oral, and eyemucosa by inoculation of the virus (4). Despite the large number of people affected all over the world with this disease affecting all age groups, dataon clinical features and prognostic factors in children and adolescents are still limited. This disease has a mildercourse in children than adults, and deaths from COVID-19 are less common in children. However, asymptomaticchildren may also play an important role in the spread of COVID-19 (5). Hence, infection control measures areof paramount importance. This paper has been prepared using the current guidelines and it includes the strategies for infection preventionand control and the clinical experiences during the coronavirus pandemic in Turkey. The current treatment pro tocols recommended in children with COVID-19 were also summarized. AU - TEZER, HASAN AU - DENİZ, MELİS DO - 10.14744/etd.2020.84565 PY - 2021 JO - Erciyes Medical Journal VL - 43 IS - 2 SN - 2149-2247 SP - 107 EP - 109 DB - TRDizin UR - http://search/yayin/detay/486754 ER -